Yomeishu to Exit Hisamitsu Stake, Books ¥413 Million Extraordinary Gain

Yomeishu Seizo Co., Ltd. ( (JP:2540) ) has provided an announcement.

Yomeishu Seizo Co., Ltd. has resolved to participate in a tender offer launched by Taiyo Kosan Co., Inc. for all 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. that it currently holds as strategic equity, citing the offer’s reasonable pricing and the Hisamitsu board’s support as factors that enhance its own corporate value. The shares will be tendered at 6,082 yen per share, for expected proceeds of about 614 million yen and an extraordinary gain of 413 million yen in the fiscal year ending March 31, 2026, though the company says its earnings forecast remains unchanged because gains from selling strategically held shares were already factored into its guidance.

The tender offer runs from January 7 to February 19, 2026, with settlement scheduled to begin on February 27, 2026, after which Yomeishu will hold no Hisamitsu shares. The move underscores a continued shift away from cross-shareholdings in Japan and signals Yomeishu’s efforts to optimize its portfolio and improve capital efficiency, while giving investors clearer visibility on the treatment of one-off gains in its current fiscal-year outlook.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

More about Yomeishu Seizo Co., Ltd.

Yomeishu Seizo Co., Ltd. is a Japanese company listed on the TSE Prime Market under securities code 2540. It operates in the health-related beverages and pharmaceuticals field, with a focus on strategic equity holdings that support its corporate value and long-term financial stability.

Average Trading Volume: 56,060

Technical Sentiment Signal: Buy

Current Market Cap: Yen59.78B

See more data about 2540 stock on TipRanks’ Stock Analysis page.